{"protocolSection": {"identificationModule": {"nctId": "NCT04730947", "orgStudyIdInfo": {"id": "20-005646"}, "organization": {"fullName": "Mayo Clinic", "class": "OTHER"}, "briefTitle": "Dapagliflozin (DAPA) Effects in HFpEF", "officialTitle": "Evaluation of the Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction (CAMEO-DAPA): A Phase II, Prospective, Double-Blind Study"}, "statusModule": {"statusVerifiedDate": "2023-09", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2021-02-24", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2022-11-17", "type": "ACTUAL"}, "completionDateStruct": {"date": "2022-11-17", "type": "ACTUAL"}, "studyFirstSubmitDate": "2021-01-27", "studyFirstSubmitQcDate": "2021-01-27", "studyFirstPostDateStruct": {"date": "2021-01-29", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2023-09-20", "resultsFirstSubmitQcDate": "2023-09-20", "resultsFirstPostDateStruct": {"date": "2023-10-12", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2023-09-20", "lastUpdatePostDateStruct": {"date": "2023-10-12", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Barry Borlaug", "investigatorTitle": "Principal Investigator", "investigatorAffiliation": "Mayo Clinic"}, "leadSponsor": {"name": "Mayo Clinic", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to determine whether treatment with Dapagliflozin (DAPA) for 6 months will improve pulmonary capillary wedge pressure (PCWP) during exercise in heart failure/preserved ejection fraction (HFpEF) and improve cardiac metabolism."}, "conditionsModule": {"conditions": ["Heart Failure With Preserved Ejection Fraction"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 38, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Dapagliflozin Group", "type": "EXPERIMENTAL", "description": "Subjects with HFpEF will take the study drug dapagliflozin daily", "interventionNames": ["Drug: Dapagliflozin"]}, {"label": "Placebo Group", "type": "PLACEBO_COMPARATOR", "description": "Subjects with HFpEF will take a placebo daily", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Dapagliflozin", "description": "10 mg orally once a day", "armGroupLabels": ["Dapagliflozin Group"]}, {"type": "DRUG", "name": "Placebo", "description": "Taken orally once a day, the placebo looks identical to the study drug but it contains no active ingredient", "armGroupLabels": ["Placebo Group"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Pulmonary Capillary Wedge Pressure (PCWP) at Maximal Exercise", "description": "Pulmonary capillary wedge pressure is a measure of cardiac filling pressure, measured using a high-fidelity micromanometer advanced through the lumen of a fluid-filled catheter during exercise.", "timeFrame": "Baseline, 24 weeks"}, {"measure": "Pulmonary Capillary Wedge Pressure (PCWP) at Rest", "description": "Pulmonary capillary wedge pressure is a measure of cardiac filling pressure, measured using a high-fidelity micromanometer advanced through the lumen of a fluid-filled catheter during rest.", "timeFrame": "Baseline, 24 weeks"}], "secondaryOutcomes": [{"measure": "Change in Body Weight", "description": "Change in body weight as measured in kilograms (kg)", "timeFrame": "Baseline, 24 weeks"}, {"measure": "Change in Total Blood Volume", "description": "Total blood volume was assessed using a radiolabeled iodinated albumin (131I, 5-25 \u03bcCu) indicator dilution technique with the BVA-100 Blood Volume Analyzer. Measured in millimeters (mL)", "timeFrame": "Baseline, 24 weeks"}, {"measure": "Change in Plasma Volume", "description": "Plasma volume was assessed using a radiolabeled iodinated albumin (131I, 5-25 \u03bcCu) indicator dilution technique with the BVA-100 Blood Volume Analyzer. Measured in millimeters (mL)", "timeFrame": "Baseline, 24 weeks"}, {"measure": "Change in Right Atrial (RA) Pressure at Maximal Exercise", "description": "Right Atrial (RA) pressure is a measure of cardiac filling pressure, measured using a high-fidelity micromanometer advanced through the lumen of a fluid-filled catheter during exercise.", "timeFrame": "Baseline, 24 weeks"}, {"measure": "Change in Right Atrial (RA) Pressure at Rest", "description": "Right Atrial (RA) pressure is a measure of cardiac filling pressure, measured using a high-fidelity micromanometer advanced through the lumen of a fluid-filled catheter during rest.", "timeFrame": "Baseline, 24 weeks"}, {"measure": "Change in Mean Pulmonary Arterial Pressure (PA) at Maximal Exercise", "description": "Pulmonary Arterial (PA) pressure is a measure of cardiac filling pressure, measured using a high-fidelity micromanometer advanced through the lumen of a fluid-filled catheter during exercise.", "timeFrame": "Baseline, 24 weeks"}, {"measure": "Change in Mean Pulmonary Arterial Pressure (PA) at Rest", "description": "Pulmonary Arterial (PA) pressure is a measure of cardiac filling pressure, measured using a high-fidelity micromanometer advanced through the lumen of a fluid-filled catheter during rest.", "timeFrame": "Baseline, 24 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Signed informed consent prior to any study specific procedures.\n* Male or female.\n* Symptoms of dyspnea (NYHA II-III) with no non-cardiac or ischemia explanation.\n* EF \u2265 50% + BMI \u2265 30 kg/m\\^2\n* Elevated pulmonary capillary wedge pressure (PCWP) during exercise (\u2265 25 mmHg) ascertained at Visit 1. Patients that have consented to study procedures but do not meet this invasive criterion will be considered as screen failures and will not be randomized .\n\nExclusion Criteria:\n\n* Type I diabetes.\n* Type II diabetes with poor control (HgbA1C \u2265 10%).\n* Recent hospitalization (\\< 30 days) or revascularization (\\< 90 days).\n* Primary cardiomyopathy (such as amyloid).\n* Constrictive pericarditis.\n* Dyspnea due to primary lung disease or myocardial ischemia in the opinion of the investigator.\n* Severe anemia (hemoglobin \\< 9gm/dl.\n* Significant left-sided valvular heart disease (\\> mild stenosis, \\> moderate regurgitation),\n* Severe kidney disease (estimated glomerular filtration rate (GFR) \\< 30) or liver disease,", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Barry A Borlaug", "affiliation": "Mayo Clinic", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Mayo Clinic in Rochester", "city": "Rochester", "state": "Minnesota", "zip": "55905", "country": "United States", "geoPoint": {"lat": 44.02163, "lon": -92.4699}}]}, "referencesModule": {"seeAlsoLinks": [{"label": "Mayo Clinic Clinical Trials", "url": "https://www.mayo.edu/research/clinical-trials"}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Dapagliflozin Group", "description": "Subjects with heart failure/preserved ejection fraction (HFpEF) will take the study drug dapagliflozin daily\n\nDapagliflozin: 10 mg orally once a day"}, {"id": "FG001", "title": "Placebo Group", "description": "Subjects with HFpEF will take a placebo daily\n\nPlacebo: Taken orally once a day, the placebo looks identical to the study drug but it contains no active ingredient"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "21"}, {"groupId": "FG001", "numSubjects": "17"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "21"}, {"groupId": "FG001", "numSubjects": "16"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Dapagliflozin Group", "description": "Subjects with HFpEF will take the study drug dapagliflozin daily\n\nDapagliflozin: 10 mg orally once a day"}, {"id": "BG001", "title": "Placebo Group", "description": "Subjects with HFpEF will take a placebo daily\n\nPlacebo: Taken orally once a day, the placebo looks identical to the study drug but it contains no active ingredient"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "21"}, {"groupId": "BG001", "value": "17"}, {"groupId": "BG002", "value": "38"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "21"}, {"groupId": "BG001", "value": "17"}, {"groupId": "BG002", "value": "38"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "67", "spread": "9"}, {"groupId": "BG001", "value": "67", "spread": "9"}, {"groupId": "BG002", "value": "67", "spread": "9"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "21"}, {"groupId": "BG001", "value": "17"}, {"groupId": "BG002", "value": "38"}]}], "categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "14"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "25"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "13"}]}]}]}, {"title": "Race and Ethnicity Not Collected", "populationDescription": "Race and Ethnicity were not collected from any participant.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "21"}, {"groupId": "BG001", "value": "17"}, {"groupId": "BG002", "value": "38"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "21"}, {"groupId": "BG001", "value": "17"}, {"groupId": "BG002", "value": "38"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Pulmonary Capillary Wedge Pressure (PCWP) at Maximal Exercise", "description": "Pulmonary capillary wedge pressure is a measure of cardiac filling pressure, measured using a high-fidelity micromanometer advanced through the lumen of a fluid-filled catheter during exercise.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline, 24 weeks", "groups": [{"id": "OG000", "title": "Dapagliflozin Group", "description": "Subjects with HFpEF will take the study drug dapagliflozin daily\n\nDapagliflozin: 10 mg orally once a day"}, {"id": "OG001", "title": "Placebo Group", "description": "Subjects with HFpEF will take a placebo daily\n\nPlacebo: Taken orally once a day, the placebo looks identical to the study drug but it contains no active ingredient"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "16"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-6.6", "spread": "7.2"}, {"groupId": "OG001", "value": "-0.4", "spread": "8.4"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.027", "statisticalMethod": "t-test, 2 sided"}]}, {"type": "PRIMARY", "title": "Pulmonary Capillary Wedge Pressure (PCWP) at Rest", "description": "Pulmonary capillary wedge pressure is a measure of cardiac filling pressure, measured using a high-fidelity micromanometer advanced through the lumen of a fluid-filled catheter during rest.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline, 24 weeks", "groups": [{"id": "OG000", "title": "Dapagliflozin Group", "description": "Subjects with HFpEF will take the study drug dapagliflozin daily\n\nDapagliflozin: 10 mg orally once a day"}, {"id": "OG001", "title": "Placebo Group", "description": "Subjects with HFpEF will take a placebo daily\n\nPlacebo: Taken orally once a day, the placebo looks identical to the study drug but it contains no active ingredient"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "16"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-2.5", "spread": "3.7"}, {"groupId": "OG001", "value": "1.1", "spread": "5.9"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.029", "statisticalMethod": "t-test, 2 sided"}]}, {"type": "SECONDARY", "title": "Change in Body Weight", "description": "Change in body weight as measured in kilograms (kg)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "kg", "timeFrame": "Baseline, 24 weeks", "groups": [{"id": "OG000", "title": "Dapagliflozin Group", "description": "Subjects with HFpEF will take the study drug dapagliflozin daily\n\nDapagliflozin: 10 mg orally once a day"}, {"id": "OG001", "title": "Placebo Group", "description": "Subjects with HFpEF will take a placebo daily\n\nPlacebo: Taken orally once a day, the placebo looks identical to the study drug but it contains no active ingredient"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "16"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-3.7", "spread": "4.2"}, {"groupId": "OG001", "value": "-0.2", "spread": "2.6"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.006", "statisticalMethod": "t-test, 2 sided"}]}, {"type": "SECONDARY", "title": "Change in Total Blood Volume", "description": "Total blood volume was assessed using a radiolabeled iodinated albumin (131I, 5-25 \u03bcCu) indicator dilution technique with the BVA-100 Blood Volume Analyzer. Measured in millimeters (mL)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mL", "timeFrame": "Baseline, 24 weeks", "groups": [{"id": "OG000", "title": "Dapagliflozin Group", "description": "Subjects with HFpEF will take the study drug dapagliflozin daily\n\nDapagliflozin: 10 mg orally once a day"}, {"id": "OG001", "title": "Placebo Group", "description": "Subjects with HFpEF will take a placebo daily\n\nPlacebo: Taken orally once a day, the placebo looks identical to the study drug but it contains no active ingredient"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "16"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-118", "spread": "542"}, {"groupId": "OG001", "value": "142", "spread": "399"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.12", "statisticalMethod": "t-test, 2 sided"}]}, {"type": "SECONDARY", "title": "Change in Plasma Volume", "description": "Plasma volume was assessed using a radiolabeled iodinated albumin (131I, 5-25 \u03bcCu) indicator dilution technique with the BVA-100 Blood Volume Analyzer. Measured in millimeters (mL)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mL", "timeFrame": "Baseline, 24 weeks", "groups": [{"id": "OG000", "title": "Dapagliflozin Group", "description": "Subjects with HFpEF will take the study drug dapagliflozin daily\n\nDapagliflozin: 10 mg orally once a day"}, {"id": "OG001", "title": "Placebo Group", "description": "Subjects with HFpEF will take a placebo daily\n\nPlacebo: Taken orally once a day, the placebo looks identical to the study drug but it contains no active ingredient"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "16"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-170", "spread": "343"}, {"groupId": "OG001", "value": "115", "spread": "322"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.014", "statisticalMethod": "t-test, 2 sided"}]}, {"type": "SECONDARY", "title": "Change in Right Atrial (RA) Pressure at Maximal Exercise", "description": "Right Atrial (RA) pressure is a measure of cardiac filling pressure, measured using a high-fidelity micromanometer advanced through the lumen of a fluid-filled catheter during exercise.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline, 24 weeks", "groups": [{"id": "OG000", "title": "Dapagliflozin Group", "description": "Subjects with HFpEF will take the study drug dapagliflozin daily\n\nDapagliflozin: 10 mg orally once a day"}, {"id": "OG001", "title": "Placebo Group", "description": "Subjects with HFpEF will take a placebo daily\n\nPlacebo: Taken orally once a day, the placebo looks identical to the study drug but it contains no active ingredient"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "16"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-3.4", "spread": "4.0"}, {"groupId": "OG001", "value": "0.8", "spread": "5.6"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.011", "statisticalMethod": "t-test, 2 sided"}]}, {"type": "SECONDARY", "title": "Change in Right Atrial (RA) Pressure at Rest", "description": "Right Atrial (RA) pressure is a measure of cardiac filling pressure, measured using a high-fidelity micromanometer advanced through the lumen of a fluid-filled catheter during rest.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline, 24 weeks", "groups": [{"id": "OG000", "title": "Dapagliflozin Group", "description": "Subjects with HFpEF will take the study drug dapagliflozin daily\n\nDapagliflozin: 10 mg orally once a day"}, {"id": "OG001", "title": "Placebo Group", "description": "Subjects with HFpEF will take a placebo daily\n\nPlacebo: Taken orally once a day, the placebo looks identical to the study drug but it contains no active ingredient"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "16"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.6", "spread": "2.6"}, {"groupId": "OG001", "value": "0.3", "spread": "4.0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.088", "statisticalMethod": "t-test, 2 sided"}]}, {"type": "SECONDARY", "title": "Change in Mean Pulmonary Arterial Pressure (PA) at Maximal Exercise", "description": "Pulmonary Arterial (PA) pressure is a measure of cardiac filling pressure, measured using a high-fidelity micromanometer advanced through the lumen of a fluid-filled catheter during exercise.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline, 24 weeks", "groups": [{"id": "OG000", "title": "Dapagliflozin Group", "description": "Subjects with HFpEF will take the study drug dapagliflozin daily\n\nDapagliflozin: 10 mg orally once a day"}, {"id": "OG001", "title": "Placebo Group", "description": "Subjects with HFpEF will take a placebo daily\n\nPlacebo: Taken orally once a day, the placebo looks identical to the study drug but it contains no active ingredient"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "16"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-5.2", "spread": "6.6"}, {"groupId": "OG001", "value": "0.7", "spread": "8.6"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.024", "statisticalMethod": "t-test, 2 sided"}]}, {"type": "SECONDARY", "title": "Change in Mean Pulmonary Arterial Pressure (PA) at Rest", "description": "Pulmonary Arterial (PA) pressure is a measure of cardiac filling pressure, measured using a high-fidelity micromanometer advanced through the lumen of a fluid-filled catheter during rest.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline, 24 weeks", "groups": [{"id": "OG000", "title": "Dapagliflozin Group", "description": "Subjects with HFpEF will take the study drug dapagliflozin daily\n\nDapagliflozin: 10 mg orally once a day"}, {"id": "OG001", "title": "Placebo Group", "description": "Subjects with HFpEF will take a placebo daily\n\nPlacebo: Taken orally once a day, the placebo looks identical to the study drug but it contains no active ingredient"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "16"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.8", "spread": "4.0"}, {"groupId": "OG001", "value": "1.1", "spread": "7.4"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.136", "statisticalMethod": "t-test, 2 sided"}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "Adverse events were collected on each participant from enrollment through approximately one week following the final on-site study visit for a total of approximately seven months.", "eventGroups": [{"id": "EG000", "title": "Dapagliflozin Group", "description": "Subjects with HFpEF will take the study drug dapagliflozin daily\n\nDapagliflozin: 10 mg orally once a day", "deathsNumAffected": 0, "deathsNumAtRisk": 21, "seriousNumAffected": 4, "seriousNumAtRisk": 21, "otherNumAffected": 21, "otherNumAtRisk": 21}, {"id": "EG001", "title": "Placebo Group", "description": "Subjects with HFpEF will take a placebo daily\n\nPlacebo: Taken orally once a day, the placebo looks identical to the study drug but it contains no active ingredient", "deathsNumAffected": 0, "deathsNumAtRisk": 17, "seriousNumAffected": 0, "seriousNumAtRisk": 17, "otherNumAffected": 17, "otherNumAtRisk": 17}], "seriousEvents": [{"term": "humerus fracture", "organSystem": "Surgical and medical procedures", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 21}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}]}, {"term": "pneumonia related to COVID-19", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 21}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}]}, {"term": "allergic food reaction", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 21}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}]}, {"term": "hospitalization", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Hospitalization due to patient not having someone to accompany them to hotel following catheterization", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 21}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 17}]}], "otherEvents": [{"term": "Minor bruising or bleeding following catheterization", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 21}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 17}]}, {"term": "Dizziness or dehydration", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 8, "numAtRisk": 21}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 17}]}, {"term": "Genitourinary infections", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 21}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 17}]}, {"term": "Hypoglycemia", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 21}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 17}]}, {"term": "Worsening dyspenea", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 6, "numAtRisk": 21}, {"groupId": "EG001", "numEvents": 7, "numAffected": 7, "numAtRisk": 17}]}, {"term": "Worsening fatigue", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 21}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 17}]}, {"term": "Medication intolerance", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 21}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 17}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": true}, "pointOfContact": {"title": "Dr. Barry A. Borlaug", "organization": "Mayo Clinic", "email": "borlaug.barry@mayo.edu", "phone": "507-293-2762"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2022-01-13", "uploadDate": "2023-09-20T15:06", "filename": "Prot_SAP_000.pdf", "size": 520812}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "C000529054", "term": "Dapagliflozin"}], "ancestors": [{"id": "D000077203", "term": "Sodium-Glucose Transporter 2 Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M348449", "name": "Dapagliflozin", "asFound": "Intramuscular", "relevance": "HIGH"}, {"id": "M1691", "name": "Sodium-Glucose Transporter 2 Inhibitors", "relevance": "LOW"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}